Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
87.76(c) 89.31(c) 88.6(c) 90.49(c) 89.69(c) Last
1 037 394 922 568 678 892 660 630 652 036 Volume
-3.17% +1.77% -0.79% +2.13% -0.88% Change
More quotes
Financials (USD)
Sales 2020 2 534 M - -
Net income 2020 -214 M - -
Net cash position 2020 1 988 M - -
P/E ratio 2020 -91,2x
Yield 2020 -
Sales 2021 2 844 M - -
Net income 2021 615 M - -
Net cash position 2021 2 644 M - -
P/E ratio 2021 32,0x
Yield 2021 -
Capitalization 19 615 M 19 615 M -
EV / Sales 2020 6,96x
EV / Sales 2021 5,97x
Nbr of Employees 1 456
Free-Float 98,7%
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and cooperation agreements (3.6%). 
More about the company
Notations Surperformance© of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INCYTE CORPORATION
10/22BRIACELL THERAPEUTICS : Breast Cancer Survival Data, 13.3 Months versus 7.2-9.8 ..
AQ
10/20INCYTE : to Report Third Quarter Financial Results
BU
10/20INCYTE CORPORATION : Provisional calendar
CO
10/13INCYTE CORPORATION : Report
CO
10/09ELI LILLY AND COMPANY : - Baricitinib has Significant Effect on Recovery Time, M..
AQ
10/08ELI LILLY AND : Lilly, Incyte Data Show 'Significant Effect' by Baricitinib on C..
DJ
10/08Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows
RE
10/08INCYTE : Baricitinib has Significant Effect on Recovery Time, Most Impactful in ..
PR
10/08INCYTE CORPORATION : Report
CO
10/07BRIACELL THERAPEUTICS : to Present Clinical Findings at the 2020 San Antonio Bre..
AQ
10/02INCYTE CORPORATION : Report
CO
10/01INCYTE CORPORATION : Report
CO
10/01INCYTE CORPORATION : Report
CO
10/01INCYTE CORPORATION : Report
CO
10/01INCYTE CORPORATION : Report
CO
More news
News in other languages on INCYTE CORPORATION
10/01MARCHÉ : fin de séance un peu décevante à Wall Street
09/29MARCHÉ : les indices US ont amplifié leurs gains initiaux
09/28WallStreet : seconde séance de hausse sans catalyseur évident
09/21Wall Street : est passé très près d'un signal de retournement
09/18Wall Street : est passé très près d'un signal de retournement
More news
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 107,44 $
Last Close Price 89,69 $
Spread / Highest target 55,0%
Spread / Average Target 19,8%
Spread / Lowest Target -3,00%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION2.71%19 615
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830